Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects
Josephine M. Forbes(Translational Research Institute), Barbora de Courten(Monash Health), Maximilian de Courten(Victoria University), Markus P. Schlaich(The University of Western Australia), Bronwyn A. Kingwell(CSL (Australia)), Melinda T. Coughlan(Baker Heart and Diabetes Institute), Georgia Soldatos(Baker Heart and Diabetes Institute), Mark E. Cooper(Australian Regenerative Medicine Institute), Vibhasha Chand(Baker Heart and Diabetes Institute), Sonia Dougherty(Baker Heart and Diabetes Institute), Jasmine G. Lyons(Baker Heart and Diabetes Institute), Karly C. Sourris(Baker Heart and Diabetes Institute), Nora E. Straznicky(Baker Heart and Diabetes Institute), David A. Bertovic(Baker Heart and Diabetes Institute)
Cited by 34
Related Papers
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
|The Lancet|2010|2.2k
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
|The Lancet|2009|2.1k
Diabetic kidney disease
|Nature Reviews Disease Primers|2015|1.2k
Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
|New England Journal of Medicine|2009|774